TrialPhase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Trial details
- Registry ID
- NCT01838395
- Phase
- Phase 2
BLRX
BioLineRx, Ltd.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
0Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsNCT01838395 | BLRX | Phase 2 | Completed | 2016-03Actual |
| Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsNCT02826486 | BLRX | Phase 2 | Completed | 2022-09-06Actual |
| A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)NCT03246529 | BLRX | Phase 3 | Active not recruiting | 2020-12-22Actual |
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
Trial details
- Registry ID
- NCT02826486
- Phase
- Phase 2
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
Trial details
- Registry ID
- NCT03246529
- Phase
- Phase 3
Latest recorded trial changes
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.